Is satelizumab (Anshiping) a chemotherapy drug?

Satralizumab (Satralizumab) is not a chemotherapy drug. It is a monoclonal antibody used to treat idiopathic neuromyelitis optica (NMOSD). Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune disease of the central nervous system (CNS) characterized by inflammatory and demyelinating lesions of the optic nerve, spinal cord, brainstem, and brain, leading to progressive impairment of vision and motor function.

Satralizumab is a disposable prefilled syringe containing 120 mg/mL satralizumab for subcutaneous injection. Recent studies have shown that interleukin-6 (IL-6) plays an important role in the immune pathogenesis of NMOSD. The exact mechanism by which satelizumab exerts its therapeutic effect in NMOSD is unclear, but it is speculated that it may involve inhibiting IL-6-mediated signaling by binding to soluble and membrane-bound IL-6 receptors. The most common side effects include the common cold (nasopharyngitis), headache, upper respiratory tract infection, inflammation of the gastric mucosa, rash, joint pain, limb pain, fatigue, and nausea.

The original drug satlizumab has been launched in China, sold under the brand name Anshiping, and is included in medical insurance. Only patients who meet the indications can be reimbursed. The specification is120mg (1ml) per box The price may be more than RMB 10,000, which is still relatively expensive; the price of each box of the original drug Saterizumab sold overseas is more than $10,000 (the price may fluctuate due to the exchange rate). The ingredients of the original drug sold domestically and abroad are basically the same. There are currently no generic versions of satlizumab available on the market.